NRx Pharmaceuticals Inc Total Liabilities
NRx Pharmaceuticals Inc total liabilities. Based on the latest financial reports, NRx Pharmaceuticals Inc (NRXPW) has total liabilities worth $25.72 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NRXPW cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of NRx Pharmaceuticals Inc (2017–2025)
Total liabilities of NRx Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how NRx Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore NRx Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
NRx Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of NRx Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Seed Capital Solutions Plc
LSE:SCSP
|
UK | GBX28.00K |
|
Housing Development and Infrastructure Limited
NSE:HDIL
|
India | Rs62.40 Billion |
|
CuriosityStream Inc
NASDAQ:CURIW
|
USA | $27.51 Million |
|
Versus Systems Inc
NASDAQ:VSSYW
|
USA | $3.46K |
|
Pathkey.ai Ltd
AU:PKY
|
Australia | AU$781.65K |
|
Us1 Critical Minerals Limited
AU:USC
|
Australia | AU$168.75K |
Liability Composition Analysis (2017–2025)
This chart breaks down NRx Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NRx Pharmaceuticals Inc asset portfolio.
Liquidity & Leverage Metrics
NRx Pharmaceuticals Inc Total Liabilities Ratios Explained
NRx Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NRx Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NRx Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of NRx Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $28.89 Million | +7.51% |
| 2024-12-31 | $26.87 Million | +41.09% |
| 2023-12-31 | $19.05 Million | +3.48% |
| 2022-12-31 | $18.41 Million | +54.38% |
| 2021-12-31 | $11.92 Million | -74.48% |
| 2020-12-31 | $46.71 Million | +1714.62% |
| 2019-12-31 | $2.57 Million | +104.72% |
| 2018-12-31 | $1.26 Million | +1249.57% |
| 2017-12-31 | $93.17K | -- |
About NRx Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone… Read more